Altogether, plasma ADAMTS13 may be a candidate biomarker for early diagnosis and referral of PAH, and vWF as a potential prognostic biomarker with possible additional value to current multiparametric risk stratification instruments. This evidence concerns the gene VWF and pulmonary arterial hypertension.